Drug to avoid hip fraction

September 3, 2015 News BioVox

UCB announced that it obtained positive results in its clinical trial with its new drug, RomosozUmab, against osteoporosis. Romosozumab is designed to work by inhibiting the protein sclerostin, thereby increasing bone formation and decreasing bone breakdown.

A Phase III clinical trial to evaluate the safety, tolerability and efficacy of RomosozUmab was performed with 436 women suffering from osteoporosis with high risk for fracture. The effect of RomosozUmab was compared to the current treatment for osteoporosis, i.e. Teriparatide, on the hip bone mineral density. A statistically significant difference was found in favor of RomosozUmab.
 


Avatar photo
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts